How Biogen’s Aduhelm Bet Became A Commercial Bust
Executive Summary
Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later.
You may also be interested in...
Biogen CEO Poses Million Dollar Question – Do We Need To Spend On Weight Loss Drugs?
As demand for Wegovy busts through capacity, Biogen’s Viehbacher asks if we need to spend on drugs for weight loss or other preventable diseases when the dollar could go towards non-preventable chronic diseases. Discussing investments at a recent conference, he was joined by Fidelity’s Rajiv Kaul who said the concept of therapeutic classes is outdated
Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.
CMS Approval Will Mark ‘Starting Gate’ For Leqembi Launch For Biogen
Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.